M-J. Ahn

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Amanda Psyrri, Jérôme Fayette, Kevin J. Harrington et al. · Annals of Oncology · 2022 · 144 citations · Full text

Medicine, Immunology, Oncology +17

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Anthony T.�C. Chan, V.H.F. Lee, R-L. Hong et al. · Annals of Oncology · 2022 · 107 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

Ezra E.W. Cohen, Kevin J. Harrington, Christophe Le Tourneau et al. · Annals of Oncology · 2017 · 90 citations

Medicine, Oncology, Pharmacotherapy +10

LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

Keiko Goto, K. Sang-We, Takafumi Kubo et al. · Annals of Oncology · 2022 · 60 citations · Full text

Medicine, Oncology, Pharmacology +17

OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth et al. · Journal of Thoracic Oncology · 2019 · 56 citations · Full text

Life Sciences, Genetics, Molecular Genetics +11